Spruce Biosciences (SPRB) Stock Forecast & Price Target

Compare

324 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SPRB Analyst Ratings

Hold

0 Buy

1 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Spruce

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SPRB Stock 12 Month Forecast

Average Price Target

$10.00

▲(29.03% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Spruce Biosciences in the last 3 months. The average price target is $10.00 with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 29.03% change from the last price of $7.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","17":"$17","30":"$30","43":"$43","56":"$56"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,17,30,43,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2024","9":"Jan<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.18,8.32,8.459999999999999,8.6,8.74,8.879999999999999,9.02,9.16,9.3,9.44,9.58,9.719999999999999,9.86,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.18,8.32,8.459999999999999,8.6,8.74,8.879999999999999,9.02,9.16,9.3,9.44,9.58,9.719999999999999,9.86,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.18,8.32,8.459999999999999,8.6,8.74,8.879999999999999,9.02,9.16,9.3,9.44,9.58,9.719999999999999,9.86,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":52.93,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.93,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.8,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.58,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.82,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.48,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.12,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41.09,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":31.5,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.12,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.49,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.18,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$10.00

Average Price Target$10.00

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Schwartz

Leerink Partners

$1→$10

Hold

29.03%

Upside

Reiterated

08/20/25

Cautious Optimism for Spruce Biosciences Amid Promising Data and Financial Uncertainty

Gregory Renza

RBC Capital

$0.5

Hold

-93.55%

Downside

Reiterated

05/06/25

Analysts Conflicted on These Healthcare Names: Spruce Biosciences (Other OTC: SPRB), Cigna (NYSE: CI) and Axsome Therapeutics (NASDAQ: AXSM)

Jonathan Wolleben

Citizens JMP

―

Hold

―

Reiterated

04/23/25

Citizens JMP reiterates Market Perform Rating on Spruce Biosciences, Inc. (SPRB)Citizens JMP analyst Jonathan Wolleben reiterated a Market Perform rating and {REMOVEPT} price target on Spruce Biosciences, Inc. (NASDAQ: SPRB).

Leland Gershell

Oppenheimer

―

Hold

―

Downgraded

12/11/24

Spruce Biosciences Downgraded to Hold Amid Unmet Clinical Trial Endpoints and Strategic Reevaluation

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Schwartz

Leerink Partners

$1→$10

Hold

29.03%

Upside

Reiterated

08/20/25

Cautious Optimism for Spruce Biosciences Amid Promising Data and Financial Uncertainty

Gregory Renza

RBC Capital

$0.5

Hold

-93.55%

Downside

Reiterated

05/06/25

Analysts Conflicted on These Healthcare Names: Spruce Biosciences (Other OTC: SPRB), Cigna (NYSE: CI) and Axsome Therapeutics (NASDAQ: AXSM)

Jonathan Wolleben

Citizens JMP

―

Hold

―

Reiterated

04/23/25

Leland Gershell

Oppenheimer

―

Hold

―

Downgraded

12/11/24

Spruce Biosciences Downgraded to Hold Amid Unmet Clinical Trial Endpoints and Strategic Reevaluation

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

SPRB Analyst Recommendation Trends

Rating

Dec 24

Jan 25

Apr 25

May 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SPRB has received 0 Buy Ratings, 9 Hold Ratings, and 1 Sell Ratings. SPRB average Analyst price target in the past 3 months is 10.00.

Each month's total comprises the sum of three months' worth of ratings.

SPRB Financial Forecast

SPRB Earnings Forecast

Next quarter’s earnings estimate for SPRB is -$15.56 with a range of -$15.56 to -$15.56. The previous quarter’s EPS was -$3.50. SPRB beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year SPRB has Outperformed its overall industry.

SPRB Sales Forecast

Next quarter’s sales forecast for SPRB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SPRB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year SPRB has Preformed in-line its overall industry.

SPRB Stock Forecast FAQ

What is SPRB’s average 12-month price target, according to analysts?

Based on analyst ratings, Spruce Biosciences’s 12-month average price target is 10.00.

What is SPRB’s upside potential, based on the analysts’ average price target?

Spruce Biosciences has 29.03% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SPRB a Buy, Sell or Hold?

Spruce Biosciences has a consensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

What is Spruce Biosciences’s price target?

The average price target for Spruce Biosciences is 10.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $10.00. The average price target represents 29.03% Increase from the current price of $7.75.

What do analysts say about Spruce Biosciences?

Spruce Biosciences’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of SPRB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Spruce Biosciences (SPRB) Stock Forecast & Price Target

SPRB Analyst Ratings

SPRB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

SPRB Analyst Recommendation Trends

SPRB Financial Forecast

SPRB Earnings Forecast

SPRB Sales Forecast

SPRB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts